Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently executed significant stock transactions according to a recent SEC filing. On February 7, ...

Johnson & Johnson (NYSE: JNJ ... s top-selling drugs is now facing biosimilar competition, weighing on its stock price growth lately. If you want upside with a smoother ride than an individual ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Johnson & Johnson is expected to post earnings ...

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide. It is set to report its Q1 2025 earnings on April 15. Wall Street ...

Johnson & Johnson (NYSE:JNJ) has had a rough three months with its share price down 11%. However, stock prices are usually driven by a company’s financials over the long term, which in this case ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Johnson & Johnson is expected ...

Compared to the aggregate P/E ratio of the 27.1 in the Pharmaceuticals industry, Johnson & Johnson Inc. has a lower P/E ratio ...